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Identification of rare Epstein-Barr virus infected
memory B cells and plasma cells in non-monomorphic
post-transplant lymphoproliferative disorders and the
signature of viral signaling
Epstein-Barr virus (EBV)-associatedpost-transplant lymphoproliferativedisorders (PTLD)1 are a significant
cause of mortality and morbidity in patients
who have undergone heterologous organ
transplantation. In these cases, EBV can not
be properly controlled by the host and de
novo infection or re-activation of a previous
infection leads to lymphoproliferative dis-
ease.2 Morphological and molecular analysis
shows a spectrum of entities, ranging from
early cases (plasmacytic hyperplasia, infec-
tious mononucleosis-like PTLD) to polymor-
phic PTLD, and to aggressive post-transplant
lymphomas (monomorphic PTLD), these
last behaving similarly to de novo lymphomas
in untransplanted patients.1
Cases of PTLD in all categories, but more
often early cases, may regress after reduction
of the immunosuppression. This suggests
that, irrespective of the composition of the
clone, some cases behave more like benign
reactive proliferations, not unlike infectious
mononucleosis,2 and are still responsive to
immune modulation. Molecular analysis of
early and polymorphic PTLD cases does
indeed show clonal EBV infection in poly-,
oligo- or monoclonal populations (by Ig VH
analysis), no alterations of major proto-onco-
genes (BCL1, BCL2, RAS, cMYC, p53) and
mutation of BCL6 in a fraction of the cases.3,4
In contrast, monomorphic PTLD are mono-
clonal according VH analysis and have a
higher frequency of multiple genetic
lesions.3,4 Thus, the accumulation of molecu-
lar lesions in PTLD parallels clinical progres-
sion and the acquisition of frankly malignant
features in previously benign, EBV-driven
unchecked growth.
The molecular mechanism by which EBV
enters and transforms B cells has been exten-
sively studied.5,6 The first viral gene to be
transcribed after infection, EBNA2, is a
potent transactivator  of LMP1 and LMP2A,
and numerous cellular genes, including
cMYC.7,8 LMP1, functionally similar to
CD40, acts as a constitutively activated
receptor9 and can activate NF-κB signaling
and downstream genes: the anti-apoptotic
bfl-1 gene,10 chemokines such as CCL17 and
CCL22,11 JunB, IRF-4, TRAF1, and BCL2L1
(BCL-XL).12 In vitro infected B cells and in vivo
naïve B cells display the growth latency pro-
gram,13 also defined as latency III status,2 in
which EBNA2, LMP1, LMP2A and other
viral genes are expressed and sustain the
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Background and Objectives. In early and polymorphic post-transplant lymphoprolifera-
tive disorders (PTLD) Epstein-Barr virus (EBV), through its latency proteins, drives the
proliferation of B lymphocytes, a process which in immunocompetent individuals leads
to the establishment of latently infected memory B cells. 
Design and Methods. We analyzed 11 cases, which included early and polymorphic
PTLD, and 12 controls for latency of EBV infection and their antigenic profile. 
Results. We identified a minority of terminally differentiated EBER+ IRTA1+ memory B
cells and EBER+ CD138+ PRDM1+ plasma cells in these samples. These elements were
identified both in PTLD and in tumor-free tonsils from post-transplant patients but not
in EBV– control tonsils. The expression of EBV latency proteins is heterogeneous, and
is associated with activation of the NF-κB pathway. EBV signaling (through EBNA2,
LMP1 and LMP2A) and NF-κB activation correlated with upregulation of target proteins:
cMYC, JunB, CCL22, TRAF1 and IRF4. EBV-infected lymphocytes in early and polymor-
phic PTLDs represent a mixture of latencies II, III and, in at least 1/3 of infected cells,
of latency 0. 
Interpretation and conclusions. EBV infection correlates with NF-κB activation, with EBV-
dependent cell signaling, and lastly, with the presence of EBV-infected plasma cells and
memory cells.
Key words: post-transplant lymphoproliferative disorder, Epstein-Barr virus, viral
latency, NF-κB signaling, plasma cell, memory B cell.
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indefinite growth of infected B cells. To escape elimina-
tion by cytotoxic T cells and establish long-term latent
infection, EBV+ cells switch to the default program6,14 or
latency II:2 EBNA2 is silenced and LMP1, LMP2A and
EBNA1 are expressed. This program allows EBV+ B cells
to enter and exploit the B-cell differentiation pathway,
where LMP1 and LMP2A may counteract a possible
negative selection due to lack of CD154 or B-cell recep-
tor (BCR) stimulation.15 Latency I, defined by expression
of EBER and EBNA1, has been documented only in
Burkitt’s lymphoma and primary effusion lymphoma.5
EBNA1  is a DNA-binding protein, which is necessary
for the maintanance of viral episome. EBER are EBV-
encoded regulatory short RNA, ubiquitously expressed
in any type of latency. EBV-infected lymphocytes may
enter the lytic cycle by expressing BZLF1,16 resulting in
production of new virions. Laichalk et al. demonstrated
that, in normal tonsils, BZLF1 expression could be
detected only in small number of plasma cells,16 suggest-
ing that latently infected lymphocytes differentiating
into plasma cells undergo viral replication.  Latent infec-
tion in the majority of cells results in permanent lodging
of EBV in a phenotypically defined marginal zone or
memory B-cell compartment  with a more restricted
latency program (LMP2A and EBER only,13,17 latency 0).5,13,
17 From there, B cells will recirculate and seed the periph-
eral lymphoid system. The majority of monomorphic
PTLD and a fraction of polyPTLD are believed to origi-
nate in or have transited through the germinal center
(GC).18,19 Early and polymorphic PTLD are, however,
valuable models for understanding of biology of EBV-
associated diseases, given the fact that they harbor
fewer additional genetic aberrations,4,20 consistent with
an earlier phase of lymphomagenesis.  In order to char-
acterize the phenotypic changes and the signaling path-
ways associated with PTLD, we studied the dynamics
of latency changes in early and polymorphic PTLD and
the expression profiles of proteins, regulated by EBV
latency –associated factors.
Design and Methods
Patients and cell line
Surgical specimens were obtained from the files of the
Department of Pathology, Columbia University Medical
Center, New York, after informed consent and/or
exemption from it was obtained, according to CU and
federal provisions. PTLD cases and controls are listed in
Table 1. A tissue microarray was constructed using a
Beecher Instruments microarrayer (Silver Spring, MD,
USA) as previously described in detail.21
In situ hybridization
EBV status was assessed by using in situ hybridization
for EBV-encoded small RNA (EBER; Novocastra,
Newcastle-Upon-Tyne, England). For double in situ
hybridization and immunohistochemistry (see below),
the hybridization was done first, then the slides were
briefly boiled in antigen retrieval solution and immuno-
histochemical analyses performed for antibodies surviv-
ing the in situ hybridization procedure. The in situ
hybridization chromagen products survive boiling.
Immunohistochemistry
The antibodies, listed in Table 2, and the double
immunohistochemistry and immunofluorescence tech-
niques used have been previously published.22,23 Briefly,
antigen retrieval was performed on deparaffinized
slides in 1mM EDTA pH.8, then a first single indirect
immunohistochemical reaction was performed with
either alkaline phosphatase- (AP) or biotinylated-sec-
ondary antibodies, followed by avidin-HRP and
NBT/BCIP or AEC color development, respectively. The
slides were then briefly boiled in 1 mM EDTA antigen
retrieval solution pH 8, a second indirect immunohisto-
chemical stain was applied with a non-cross-reacting
reagent, and the slides were finally developed with a
contrasting color.
Immunofluorescence
Double immunofluorescence was performed with
primary antibodies raised in different species or of dif-
ferent isotypes, counterstained with fluorochrome-con-
jugated, species- or isotype-specific secondary antibod-
ies.22 Tyramide signal amplification of LMP1 and
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Table 1. Clinical characteristics of post-transplant patients with PTLD
and control cases.
Case# Diagnosis Biopsy Age Sex Organ Months
site transplanted after
transplant
#1 IM-like PTLD Tonsil and 4 M Liver 26
Adenoids
#2 polyPTLD Lymph node 7 M Heart >36
#3 polyPTLD Small bowel 10 M Kidney NA
#4 polyPTLD Lymph node 26 F Kidney 8
#5 polyPTLD Lymph node 19 M Heart 48
#6 polyPTLD Tonsil and 7 F Heart 30
Adenoids
#7 polyPTLD Palate 7 F Heart 63
#8 polyPTLD Cecum 16 M Heart NA
#9 polyPTLD Lymph node 3 F Liver 35
#10 monoPTLD Lymph node 10 M Heart >72
#11 monoPTLD Tonsil and 18 F Kidney >48
Adenoids
#12-16 controlT&A* Tonsil and 2-32 1M,4F none na
Adenoids
#17-23 pTxT&A* Tonsil and 2-8 3M,4F Heart, 19-64
Adenoids Liver
control tissues* various na na none na
*controlT&A: non transplant Tonsil and Adenoids; pTxT&A: post-transplant Tonsil
and Adenoids; normal spleen (2), lymph nodes (14), thymus (1), CLL (1), mantle cell
NHL (1), marginal zone NHL (4), follicular lymphoma (1), Non- Hodgkin lym-
phoma (7), three of which EBV+ DLCL in HIV.
EBNA2 staining was performed according to the manu-
facturer’s instructions (Perkin-Elmer, Wellesley, MA,
USA) on avidin-HRP-counterstained immunostains, fol-
lowed by Tyramide-FITC. The slides were counter-
stained with DAPI and mounted (Molecular Probes,
Eugene, OR, USA). Gray scale images were taken and
mounted using Adobe Photoshop software.
Polymerase chain reaction analysis of
immunoglobulin heavy chain gene rearrangement
DNA was extracted from paraffin embedded tissue
using the Qiamp kit (Qiagen, Valencia, CA, USA),
amplified using previously published primers,24 and sub-
jected to heteroduplex analysis and electrophoresis on a
precast 4-20% polyacrylamide gel (Invitrogen,
Carlsbad, CA, USA). A sharp band which persisted fol-
lowing heteroduplexing was considered evidence of
clonal immunoglobulin heavy chain gene rearrange-
ment.
Results 
The clinical and pathological features of the post-
transplant and control cases are listed in Table 1.
Expression of  EBNA2, LMP1, LMP2A and EBER
Lesions were classified according to the WHO classi-
fication system.1 Five samples of tonsils and adenoids
(tonsils) from non-transplant patients had no EBER+ cells
or too few to be evaluable by double-staining experi-
ments; Tonsils from transplant patients without PTLD
(pTxTonsils) had rare EBER+ cells/high power field. IM-
like, polymorphic and monomorphic PTLD had  pro-
gressively increasing numbers of EBER+ cells, reaching
nearly 100% of cells (Table 3 and Figure 1A). EBER+ cells
ranged morphologically from small lymphocytes to
immunoblasts and Reed-Sternberg-like cells.
In pTxTonsils with reactive follicular hyperplasia,
EBER+ cells were localized predominantly in subepithe-
lial and interfollicular areas with occasional cells being
found in the mantle zone. In IM-like, polymorphic and
monomorphic PTLD the distribution of EBER+ cells was
diffuse.  The EBER+ cells matched the frequency and dis-
tribution of lesional cells in each sample. Five out of
seven pTxTonsils, which contained small number of
EBER+ cells, had no detectable expression of EBNA2,
LMP1 or LMP2A (Figure 1B).
In early (IM-like) and polymorphic PTLPD, up to 90%
of cells were EBER+, but only a subset of EBER+ cells
expressed EBNA2 and/or LMP1 (see Table 3).
Comparing the staining for LMP1 and EBNA2 with
findings of EBER in situ hybridization showed that
>70% of the infected B cells (defined by Pax5 [not shown]
or CD79a expression), lacked latency II and III viral pro-
teins, as found in six out of seven polyPTLD cases
(Figure 1A). Staining for LMP2A revealed  positive cells
exclusively in polymorphic PTLD: scattered positive
cells were identified in five out of eight cases. BZLF1
staining revealed rare scattered positive cells in three out
of eight polymorphic PTLD. No other cases expressed
lytic protein. BZLF1+ cells were negative for CD20,
CD138 and IRTA1 (data not shown) in PTLD and positive
for CD20 in the EBV+ Burkitt control cell line. Thus,
early and polymorphic PTLD represent a mixture of
EBV-infected lymphocytes with variable expression of
latency factors, predominantly in latency I or 5.
Expression of EBNA2 and LMP1-regulated target
proteins
EBNA2 was detected in four cases, three of which
were polyPTLD. cMYC is directly upregulated by
EBNA2:25 all EBNA2+ cases were cMYC+, and most of
the cells co-expressed both antigens (Figure 2A1-A2,
Table 3 and supplemental Figure 1). Four additional
cases were EBNA2- cMYC+ (Figure 2A3-A4). By double
CD20-staining, all cMYC+ cells were B cells (not shown).
EBV-infected memory and plasma cells in PTLD
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Table 2. Antibodies and probes.
Antibody/ Source Species Clone or Isotype Dilution
Probes serum
EBNA2 DakoCytomation mouse PE2 G1 1:200
EBV LMP1 DakoCytomation mouse CS1-4 G1 1:200
EBV LMP2A Niedobitek G rat 4E11, 15F9 G 1:50
EBER in situ Novocastra as directed
hybridization
MUM 1 Falini B., U.Perugia mouse 2H9 G1 1:50
MUM1/IRF-4 SCBT goat (sc-6059) G 1 µg/mL
c-Rel (NF-kB) Oncogene Research rabbit Ab-1 G 1:2000
CCL22 (MDC) PeproTech rabbit G 0.5 µg/mL
TRAF-1 SCBT mouse H3 G1 1 µg/mL
JunB SCBT mouse C-11 G1 1 µg/mL
BclX LabVision mouse 2H12 G2a 0.5 µg/mL
cMYC SCBT rabbit (sc-764) G 1 µg/mL
CD30            DakoCytomation mouse Ber-H2 G1 1 µg/mL
Ki-67 Gerdes J, MIB, mouse MIB 1 G1 1:50
Germany
BCL6 SCBT rabbit (sc-858) G 0.1 µg/mL
PRDM1/ KL Calame, C.U. mouse 3H2E8 G1 1:30
BLIMP-1 NY USA
IRTA1 Cattoretti G rabbit G 0.5 µg
PAX5 SCBT goat (sc1974) G 1 µg/mL
PAX5 BD mouse 24 G1 1 µg/mL
CD10 Novocastra mouse 56C6 G1 1:50
CD20 DakoCytomation mouse L26 G2a 0.5 µg/mL
CD23 Novocastra mouse 1B12 G1 1:100
CD79a LabVision rabbit SP18 G 1:200
CD138 Serotec mouse B-B4 G1 1:200
CD3e DakoCytomation rabbit G 0.5 µg/mL
CD4 Novocastra mouse CD4-1F6 G1 1:50
CD8 Novocastra mouse CD8-4B11 G2a 1:50
CD57 BD mouse HNK-1 (Leu7) M 0.5 µg/mL
TIA-1 Beckman Coulter mouse 2G9A10F5 G1 1:50
negative Sigma rabbit, mouse G 1 µg/mL
control
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Table 3. Immunophenotypic profile of PTLDs.
Case# Diagnosis Clonality 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
#1 IM-like polyclonal ++++ − + − − +++ + + ++ + + + + + ++ + + − + − Foc Remnants
#2 polyPTLD monoclonal ++++ − + − − +++ + - + + + + − − − + − − − − Remnants
#3 polyPTLD monoclonal +++ +++ ++ + − + + + +++ + + +++ + ++++ ++ - + + − − absent
#4 polyPTLD monoclonal ++++ +++ ++ + + +++ +++ + +++ + + +++ + ++ +++ − + − − − absent
#5 polyPTLD monoclonal ++++ − ++ + − +++ + ++++ - ++++ ++++ − − ++ - + − − − − absent
#6 polyPTLD polyclonal ++++ − + + + +++ +++ + ++ + + +++ +++ +++ +++ ++ +++ + +++ +++ absent
#7 polyPTLD minor + ++ + na − na + + + ++++ + + − + +++ − − − − + Scatt.cells
clonal band
#8 polyPTLD polyclonal ++ − + - − na + + + + − na ++ + na na na − + − absent
#9 polyPTLD° minor ++++ − + + + +++ ++ + ++ + + ++ ++ +++ +++ ++++ ++++ + + − Foc Remnants
clonal band
#10 monoPTLD NA +++ − +++ na − +++ ++++ ++++ + − − ++++ - ++++ ++++ - +++ - − − absent
#11 monoPTLD monoclonal +++ +++ ++ − − + ++++ + +++ − − + +++ ++++ ++++ − − − − − Scatt.cells
12-16 controlT&A 0/5 0/5 0/5 0/5 0/5 na N°° N N N na N N N N N N N 0/5 0/5 N
17-23 pTxT&A 5/7 0/7 0/7 0/7 0/7 na N N N N na N N N N N N N 1/7 4/7 N
1: EBER; 2: EBNA2*; 3: LMP1*; 4: LMP2A*; 5: BZLF1; 6: EBER+ LMP1-EBNA2-; 7: JunB/CD20**; 8: JunB/LMP1; 9: TRAF-1/PAX-5; 10: cREL/CD20; 11:
cREL/LMP1; 12: CCL22/Pax5; 13: MUM1/CD20; 14: CD30; 15: cMYC; 16: CD138; 17: PRDM1; 18: PRDM1+ CD20+; 19: CD138+EBER+; 20: IRTA1+EBER+
; 21: CD23+ DRC. *EBNA2, LMP1, LMP2A was scored on an arbitrary 5 points scale (-, +,  ++, +++, ++++). All other staining were scored according to the % of positive
cells (nil: -, 1%-10%: +, 11%-20%: ++, 21%-50%: +++, >50%: ++++). **Staining scores for the first antigen in front of the slash is the numerator, the antigen after the
slash is the denominator. °This case contained lambda restricted B cell population and a clone with a 47, XX, t(1;13) (p36;p21), + mar 1[cp18]. °°n=normal distribu-
tion, as observed in normal lymphoid tissue. Na: not available.
Figure 1. Latency pattern in PTLD. Three
representative samples of pTxT&A (A),
and polyPTLD (B,C) are shown, hybridized
for EBER (black, top row) and for LMP1+
EBNA2 versus CD79a (low power middle
row, high power bottom row; red CD79a,
green LMP1+EBNA2. Light DAPI counter-
stain in blue). Note rare EBV+ cells at the
border of two GC (stars) in histologically
normal tonsil in (A). Arrows point to
CD79a dim/negative infected B cells;
LMP2A expression (D,E) in a case of
polyPTLD. Scale bar: 40 µm upper and

















cMYC  was heterogeneously positive on large CD30+
blasts. The smaller, strongly EBNA2+ cMYC+ B cells
were usually CD30- (Figure 2 A2,A4,A5).
We then determined the expression of a group of
genes, regulated by LMP-1, based on transcriptional
profiling and other in vitro studies: TRAF1, c-Rel, IRF4,
CCL22, JUN-B, BCL2L1 (BCL-XL), CD10 and BCL6.26,27
Each case was double-stained for LMP1 and for B-
restricted markers (CD20, Pax5) in order to selectively
evaluate the infected B cells. LMP1+ cells in all PTLD
cases contained variable proportions of cytoplasmic and
nuclear c-Rel (N-cRel) (Figure 2A6). Notably, small
LMP1-, N-cRel+ cells were often observed. Double-
staining for CD30 and c-Rel gave similar results (Figure
2A7). LMP1+ cells were also JunB+ and contained vari-
able amounts of CCL22 (Figure 2 A8-A9). The frequen-
cy and distribution of Pax5+ B cells were similar to those
of LMP1+ cells. CD79a was often weak or markedly
reduced in LMP1+ cells (Figure 1).
To assess the proliferative status of lesional cells, dou-
ble staining for LMP1 and p27 was performed and
showed mutually exclusive staining in each case (Figure
EBV-infected memory and plasma cells in PTLD
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Figure 2A.  EBV signaling and B-cell differentiation in normal tonsil (T) and PTLD. A. An EBNA2+ PTLD coexpress EBNA2 (black) and CD20
(red) (A1), cMYC (black) and CD30 (red) (A2). Another PTLD is EBNA2-negative and expresses only cMYC (black) on CD20+ (red, A3)
CD30+ cells (red, A4).  An EBNA2- cMYC- case is shown in with rare CD30+ cells (red, A5). LMP1+ (red) infected cells are heterogeneous-
ly positive for nuclear cRel (green, arrow A6) and surrounded by nuclear (arrowhead) or cytoplasmic (double arrowhead) positive cells,
LMP1-negative.  Nuclear cRel (green) is expressed in part of the CD30+ (red) cells (A7).  LMP1+ cells (red) contain nuclear JunB (black,
A8) and CCL22 (black, A9). LMP1 (red) and nuclear p27 (black) are mutually exclusive (A10). Scale bar = 1 µm. B. PRDM1+ lympho-
cytes (black) are distributed subepithelially, interfollicularly (asterisk) and inside a CD20+ (red) germinal center (B1). In the inset PRDM1
is expressed in CD20- plasma cell precursors and in CD20+ centrocytes (arrows). PRDM1+ (black) CD20+ (red) or CD20- elements are
seen in PTLD (B2). PRDM1+ lymphocytes (black) coexpress CD138 (red) in the subepithelium (arrow and right inset), but are CD138-
negative in the GC (asterisk and left inset (B3). PRDM1+ lymphocytes (black) are heterogeneously CD138+ (red) in PTLD (B4). CD138+
plasma cells and epithelial cells (red) are EBER negative (B5). In the inset a rare EBER+ cell (blue) is stained by CD138 amidst nega-
tive plasma cells. Numerous CD138+ plasmacytoid cells and plasma cells (red) are EBER+ (blue) in PTLD (B6). IRTA1+ subepithelial lym-
phocytes (red) are EBER- (blue) (B7). In the inset rare EBER+ cells (blue) are stained by IRTA1 amidst negative cells in a normal Post
Txp Tonsil. Numerous IRTA1+ (red) cells are EBER+ (blue) in PTLD (B8). A low power image of a normal tonsil core with preserved
immunoarchitecture, highlighted by interfollicular IRTA1+ cells. (B9) Disrupted architecture in a tonsil core stained for IRTA1 (black). In
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2 A10) and in the latency III-type cell lines (not shown). As
for N-cRel, a range of positivity for p27 was noted in
LMP1-, CD20+ cells.  BCL2L1 (BCL-XL) staining was
broadly present on normal and pathologic B-cell subsets
(not shown) and was therefore not further evaluated.  All
of our PTLD were CD10_; BCL6 expression was very
weak in a subset of cells, never exceeding positivity of
15% of cells in any given category of PTLD (data not
shown). In summary, PTLD show NF-κB activation and
expression of proteins associated with EBNA2 and
LMP1 signaling.
Terminal B-cell differentiation in PTLD
CD40 and BCR signaling  are required for activation
and differentiation of antigen-specific B cells. Having
found evidence of EBNA2- and LMP1-associated signal-
ing, we evaluated terminal differentiation in our sam-
ples using plasma cell and memory cell markers.
PRDM1, a master regulator of plasma cell differentia-
tion stained in control tonsils and pTx tonsils a subpop-
ulation of B cells inside the GC and subepithelial plasma
cells, as previously described.22 The expression of
PRDM1 in PTLD was variable and ranged from 5% in
early lesions, to up to 50% in polymorphic lesions, cor-
relating with CD138 expression (Table 3, Figure 2).
Double staining for PRDM1 and CD3, CD20 and
CD138 demonstrated that the overwhelming majority
of PRDM1+ cells are CD138+ plasma cells, with a minor-
ity having a CD20+/PRDM1+/CD138– pre-plasma cell
phenotype (Figure 2 B1,B2,B6,B7). No CD3/PRDM1
double positive cells were detected in our cases. LPM1
and PRDM1 staining was mutually exclusive (not
shown).
To investigate the role of EBV in plasma cell differen-
tiation we double stained for EBER and CD138.  In early
IM-like PTLD there were rare CD138/EBER double-pos-
itive cells. Three out of eight polymorphic PTLD cases
had CD138/EBER double positive cells, including a case
that was monoclonal according to VH analysis, had
light chain restriction and bore clonal karyotypic abnor-
mality (Fig.2B). In these three cases, EBER expression in
plasma cells was relatively weak. EBER+ plasma cells
were not detected in five control tonsils, but were seen
in one out of seven pTxTonsils (Figure 2 B3, B8).
FCRL4 (IRTA1) identifies a subset of memory B cells
in tissue.28 In all cases, IRTA1+ cells were enriched for in
interfollicular areas (Figure 2B). IRTA1+ memory cells
were also present in six out of eight polymorphic PTLD,
with reduced numbers and with a disorganized pattern,
compared to in normal tonsils  (Figure 2 B9). Four out of
seven pTxTonsils and two out of eight polymorphic
PTLD cases contained IRTA1/EBER-positive cells. EBER
expression in IRTA1+ cells was weak or negligible
(Figure 2 and Table 3). In three cases we detected EBNA-
2+/IRTA1+ cells (Figure 2). A case of non-transplant relat-
ed IM did show EBER+ and EBNA2+ IRTA1+ cells (not
shown). Double staining for LMP1 and IRTA1 in two
cases did not reveal co-expression (not shown).
Discussion
Biological significance of EBV-infected plasma cells
and memory B cells in PTLD
We have identified for the first time in polymorphic
PTLD a small subset of EBV-infected terminally differ-
entiated memory B cells and plasma cells. These cells
morphologically and phenotypically resemble their
uninfected counterpart, but contain the virus in a latent
phase (see below). The reason why only the minority of
plasma cells contain EBER is unclear. One possibility is
low absolute sensitivity of chromogenic detection of
EBER, although other infected lymphocytes demon-
strate consistently stronger staining. Another possibility
is that EBER-positive plasma cells selectively die, leav-
ing the non-infected plasma cells in a majority. This pos-
sibility is not likely, since EBV induces plasma cell death
through the induction of BZLF1 expression and the lytic
cycle,16 and we did not detect BZLF1 expression in
CD138+ plasma cells. We favor the hypothesis that,
upon establishment of latency, EBER is downregulated
in a substantial fraction of plasma cells and memory
cells, possibly via methylation of the viral genome.29
The leading candidate for such repression in plasma
cells is PRDM1, known to recruit methyltransferases to
genomic targets.30 Other mechanisms may be at play in
memory B cells, including a global reduction of RNA
synthetic activity associated with quiescence. We can-
not discriminate primary infection of naïve B cells from
re-infection of terminally differentiated B cells, since,
irrespectively of the putative origin, all differentiated
cells consistently display a latent infection viral profile
(see below). EBV+ plasma cells had already been identi-
fied in samples from patients with infectious mononu-
cleosis.31
Critical role of EBV-dependent NF-κB activation in
shaping PTLD biology
Antigen-dependent stimulation of the antigen recep-
tor in normal cells, together with engagement of CD40
and other co-stimulatory molecules, ultimately leads to
NF-κB-mediated terminal B-cell differentiation as mem-
ory or secretory mature B cells.26 EBV is thought to
exploit this very same mechanism via surrogate mole-
cules, such as LMP1 and LMP2A.9,15,32
We identified NF-κB activation in LMP1+ cells in all
polyPTLD by tracing the nuclear translocation of c-Rel,
a member of the NF-κB family. Nuclear relocation of c-
Rel was previously validated to be proof of NF-κB acti-
vation in human lymphomas.23,33,34 LMP1 expression was
detected in cells that were IRTA1– and PRDM1– and,
therefore, not terminally differentiated. In polymorphic
R. Shaknovich et al.
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PTLD, abundant membranous LMP1 does not corre-
spond to ubiquitous relocation of c-Rel. The reason for
this is unclear. One possibility is that other NF-κB fam-
ily members (p65, p50) may be activated first, followed
by c-Rel. We could not reproducibly use other available
anti NF-κB antibodies on our material, therefore this is
a possibility that remains to be investigated. 
N-cRel+, LMP1– small lymphoid cells were also noted.
This may be the  evidence that other molecules besides
LMP1 provide NF-κB signaling, such as CD154. It has
been shown that CD40 ligation downregulates EBNA2
and LMP135. LMP1 and CD40 signaling both suppress
entry into the viral lytic cycle and, together with
LMP2A, contribute to progression toward a latent infec-
tion.36 Finally, the heterogeneity in the association
between LMP1 and N-cRel may reflect the short, tran-
sient, oscillating presence of c-Rel in the nucleus in
physiologic conditions in normal cells37 as opposed to in
established lymphomas and cell lines.23,33,34
Consistently with the evidence of NF-κB-mediated
signaling, a number of downstream up-or downregulat-
ed genes were found to be expressed or absent in the
infected B cells: Jun-B, CCL22, TRAF1, IRF4 (upregulat-
ed) and CD10, BCL611,27,38 (downregulated). Our data are
highly suggestive that ongoing, EBV-induced NF-κB sig-
naling in a subset of infected B cells leads to these cells’
terminal differentiation toward the memory or plasma
cells and to the establishment of viral latency.
The EBV lytic cycle, associated with BLZF1 expres-
sion and plasma cell differentiation,16 was observed in a
very small proportion of cells in a few cases; these
observations were inadequate to draw any conclusions,
except for the rarity of the EBV lytic cycle in PTLD in
vivo.
Dynamic range of EBV latencies in PTLD
In all EBV+ cases tested, EBER+ cells outnumbered the
cells expressing EBNA2, LMP1 and LMP2A, suggesting
that each case is an admixture of transitory latency
stages. The phenomenon of broadening of viral latent
gene expression during the consecutive passages of lym-
phoblastoid cell lines has been demonstrated in vitro by
Gregory et al.39. A mixed pattern of viral gene expression
has been also detected in IM.31,40 This observation may
imply that post-transplant EBV+ patients harbor pre-
dominantly latently infected memory B cells of latency
0, possibly because of ongoing NFκB signaling.
In a variable minority of cells, however, the growth
transcriptional program of EBV is epitomized by cMYC
expression. cMYC has a potent and pleiotropic growth-
promoting effect41 and is a direct activation target of
EBNA2.8 All our cases expressing EBNA2 also expressed
cMYC, although some of our polymorphic PTLD cases
expressed cMYC without EBNA2. The expression of
cMYC in the EBNA2– cases is not likely to be due to
mutations, since cMYC is largely unmutated in poly-
morphic PTLD.4,20 Upregulation of cMYC may be due to
cellular (as opposed to viral) factors, such as antigen-
dependent signaling, post-transcriptional regulation or
both.42
In addition, EBNA2 and LMP1 independently pro-
mote cell growth and replication, conditions in which
entry into the cell cycle is favored by removal of
inhibitory molecules such as p278. Indeed, we showed
mutually exclusive expression of LMP1 and p27 in all
cases of PTLD analyzed. None of our samples showed
cytoplasmic sequestration of p27 or elevated cyclin D1
expression (not shown), both known mechanisms for
bypassing p27-mediated growth arrest. We therefore
conclude that polymorphic PTLD retain a normal regu-
lation of p27.
Based on these findings, we conclude that in early and
polymporphic PTLD lesions there is ongoing LMP1- and
possibly LPM2A-mediated, EBV-dependent signaling,
which recapitulates and mimics physiologic B-cell
receptor signaling, leading to the terminal differentia-
tion of infected B cells. Greater understanding of PTLD
biology may lead to better therapeutic strategies for
EBV-associated diseases including lymphomas. 
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